Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942994 · ClinicalTrials.gov registry record · Phase 4
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 412
- Enrollment target
NCT00942994 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 412 participants.
The verdict
NCT00942994, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 412 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.
Interventions
- DRUG Aliskiren/Amlodipine
- DRUG Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942994
The ClinicalTrials.gov registry entry for NCT00942994 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren/Amlodipine is the first listed.
NCT00942994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942994 about?
NCT00942994 is a clinical study titled "Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension". The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.
What is the current status of trial NCT00942994?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 412 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00942994?
The interventions under investigation include: Aliskiren/Amlodipine (DRUG), Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ) (DRUG).
Who is sponsoring clinical trial NCT00942994?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.